Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 2/20 | 0.73 |
| ▸ | CTSD | P07339 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.63 |
| ▸ | GAA | P10253 | 2/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.58 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16464436 | 0.86 | MEN1 (0.69) | HCRTR1CTSDMEN1KMT2AMAPT | |
| SCHEMBL29763776 | 0.86 | HCRTR1 (0.73) | HCRTR1MEN1KMT2AMAPTMAPK1 | |
| SCHEMBL7959716 | 0.86 | HCRTR1 (0.73) | HCRTR1MEN1KMT2AMAPTMAPK1 | |
| SCHEMBL6400854 | 0.86 | HCRTR1 (0.73) | HCRTR1MEN1KMT2AMAPTMAPK1 | |
| SCHEMBL16193193 | 0.85 | CTSD (0.68) | HCRTR1CTSDMEN1KMT2AMAPT | |
| SCHEMBL14761404 | 0.85 | CTSD (0.54) | HCRTR1CTSDMEN1KMT2AMAPT | |
| SCHEMBL30676337 | 0.85 | CTSD (0.54) | HCRTR1CTSDMEN1KMT2AMAPT | |
| SCHEMBL10257995 | 0.85 | MEN1 (0.68) | HCRTR1CTSDMEN1KMT2AMAPT | |
| SCHEMBL16829424 | 0.84 | HCRTR1 (0.81) | HCRTR1MEN1KMT2AMAPTMAPK1 | |
| SCHEMBL19531825 | 0.83 | HCRTR1 (0.69) | HCRTR1MEN1KMT2AMAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122080895-A | Polyglycolic acid composition and preparation method thereof, biodegradable polyester material and application thereof, and PGA temporary plugging ball and preparation method thereof | — | 2026-05-26 | — | — | CN | claimed |
| WO-2025020685-A1 | PEROVSKITE THIN FILM LAYER AND PREPARATION METHOD THEREFOR, AND PEROVSKITE SILICON STACKED SOLAR CELL AND PREPARATION METHOD THEREFOR | 通威太阳能（成都）有限公司 | 2025-01-30 | — | — | WO | claimed |
| CN-117416956-A | Preparation process of bamboo-based activated carbon and high-adsorptivity bamboo-based activated carbon composite adsorbent | 上犹县黄苗竹业有限公司 | 2024-01-19 | — | — | CN | claimed |
| CN-116887609-A | Perovskite thin film layer and preparation method thereof, perovskite silicon laminated solar cell and preparation method thereof | 通威太阳能（成都）有限公司 | 2023-10-13 | — | — | CN | claimed |
| CN-122080895-A | Polyglycolic acid composition and preparation method thereof, biodegradable polyester material and application thereof, and PGA temporary plugging ball and preparation method thereof | — | 2026-05-26 | — | — | CN | disclosed |
| WO-2025020685-A1 | PEROVSKITE THIN FILM LAYER AND PREPARATION METHOD THEREFOR, AND PEROVSKITE SILICON STACKED SOLAR CELL AND PREPARATION METHOD THEREFOR | 通威太阳能（成都）有限公司 | 2025-01-30 | — | — | WO | disclosed |
| CN-117416956-A | Preparation process of bamboo-based activated carbon and high-adsorptivity bamboo-based activated carbon composite adsorbent | 上犹县黄苗竹业有限公司 | 2024-01-19 | — | — | CN | disclosed |
| CN-116887609-A | Perovskite thin film layer and preparation method thereof, perovskite silicon laminated solar cell and preparation method thereof | 通威太阳能（成都）有限公司 | 2023-10-13 | — | — | CN | disclosed |
| CN-113307780-B | Preparation method of 2-amino-1, 3, 4-oxadiazole compound and compound prepared by same | 重庆医科大学 | 2023-06-06 | — | — | CN | disclosed |
| US-20220002255-A1 | UBE2K MODULATORS AND METHODS FOR THEIR USE | THLIVERIS, ANDREW T. | 2022-01-06 | — | — | US | disclosed |
| US-20210318619-A1 | COMPOSITION, METHOD OF PRODUCING SUBSTRATE, METHOD OF FORMING PATTERN, AND METHOD OF FORMING REVERSE PATTERN | JSR CORPORATION (JP) | 2021-10-14 | — | — | US | disclosed |
| CN-113307780-A | Preparation method of 2-amino-1, 3, 4-oxadiazole compound and compound prepared by same | 重庆医科大学 | 2021-08-27 | — | — | CN | disclosed |
| EP-1987024-A1 | THIOPHENE AND THIAZOLE SUBSTITUTED TRIFLUOROETHANONE DERIVATIVES AS HISTONE DEACETYLASE (HDAC) INHIBITORS | Istituto di Ricerche di Biologia Molecolare P. Angeletti (IT) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007093827-A1 | THIOPHENE AND THIAZOLE SUBSTITUTED TRIFLUOROETHANONE DERIVATIVES AS HISTONE DEACETYLASE (HDAC) INHIBITORS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2007-08-23 | — | — | WO | disclosed |
| US-7064204-B2 | Pharmaceutically active compounds having a tricyclic pyrazolotriazolopyrimidine ring structure and methods of use | KING PHARMACUETICALS RESERCH AND DEVELOPMENT, INC. (US) | 2006-06-20 | — | — | US | disclosed |
| US-7022847-B2 | Method for the production of 2-(2-ethoxyphenyl)-substituted imidazotriazinones | BAYER HEALTHCARE AKTIENGESELLSCHAFT (DE) | 2006-04-04 | — | — | US | disclosed |
| EP-1549319-A2 | PHARMACEUTICALLY ACTIVE COMPOUNDS HAVING A TRICYCLIC PYRAZOLOTRIAZOLOPYRIMIDINE RING STRUCTURE AND METHODS OF USE | King Pharmaceuticals Research and Development Inc. (US) | 2005-07-06 | — | — | EP | disclosed |
| US-20040097505-A1 | Method for the production of 2-(2-ethoxyphenyl)-substituted imidazotriazinones | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2004-05-20 | — | — | US | disclosed |
| US-20040039004-A1 | Nitrogen compounds such as 4-(5-amino-7-phenethyl-7H-pyrazolo (4,3-e)(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-phenol, used as adenosine receptor antagonists, for prophylaxis of nervous, cardiovascular, respiratory, urogenital and immune disorders | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC | 2004-02-26 | — | — | US | disclosed |
| WO-2003101455-A2 | PHARMACEUTICALLY ACTIVE COMPOUNDS HAVING A TRICYCLIC PYRAZOLOTRIAZOLOPYRIMIDINE RING STRUCTURE AND METHODS OF USE | KING PHARMACEUTICALS RESEARCH & DEVELOPMENT, INC. (US) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220002255-A1 | UBE2K MODULATORS AND METHODS FOR THEIR USE | UBE2N, UBE2B, UBE2E1 | HCRTR1 4486/4885CTSD 3342/4885MEN1 4260/4885 |
| US-20040097505-A1 | Method for the production of 2-(2-ethoxyphenyl)-substituted imidazotriazinones | IDH2, CA2, KCNH2 | HCRTR1 3185/4885CTSD 4394/4885MEN1 1133/4885 |
| US-20040039004-A1 | Nitrogen compounds such as 4-(5-amino-7-phenethyl-7H-pyrazolo (4,3-e)(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-phenol, used as adenosine receptor antagonists, for prophylaxis of nervous, cardiovascular, respiratory, urogenital and immune disorders | ADORA2A, ADORA3, ADORA1 | HCRTR1 1127/4885CTSD 2654/4885MEN1 3617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.